For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Alprostadil - Erectile dysfunction
PAD Profile : Alprostadil - Erectile dysfunction Important
Traffic Light Status
Status 1 of 2.
- Cream
Status 2 of 2.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Alprostadil intracavernosal injections and intra-urethral applications may be more effective than the alprostadil cream.
It should be initiated in secondary care, patients trained to self-administer and treatment shown to be effective before discharge for GPs to prescribe.
Alprostadil cream (Vitaros) is restricted by SLS criteria as identified in the Health Service Circular (HSC) 1999/148 at a maximum frequency of dosing of four times per month.
Alprostadil cream (Vitaros®) is now available as a treatment option in primary care for patients who do not respond to PDE-5 inhibitors. This can be initiated in primary care and is considered GREEN on the traffic light system
Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use. See here for further information https://surreyccg.res-systems.net/pad/Search/DrugConditionProfile/6168